Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05573685
Other study ID # CT-100-D-002
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 10, 2022
Est. completion date February 6, 2023

Study information

Verified date April 2023
Source Click Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

CT-100 is a platform that provides interactive, software based therapeutic components that may be used as part of a multimodal treatment in supplementary or standalone prescription or nonprescription software-based digital therapeutics (PDT/DTx), being developed by Click Therapeutics, Inc. (Click).


Description:

The Study App (CT-100-002) contains a class of Digital Neuro-activation and Modulation (DiNaMo™) mechanisms of action that are part of the Click Neurobehavioral Intervention (CNI) Platform™. DiNaMo™ provide interactive, software based therapeutic components that may be included in a multimodal treatment for developing future digital therapeutics. Chronic pain is a transdiagnostic condition which manifests in patients with diverse underlying pathologies such as rheumatoid arthritis, diabetic neuropathy, fibromyalgia, and irritable bowel syndrome. This basket study aims to evaluate the efficacy, safety, and tolerability of CT-100-002 on measures of pain, pain-related functioning, and mood across multiple indications. The study results will further future clinical development of digital therapeutics comprising DiNaMo™ mechanisms of action.


Recruitment information / eligibility

Status Completed
Enrollment 124
Est. completion date February 6, 2023
Est. primary completion date February 6, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Meets indication-specific eligibility criteria as reported by the study participant with adequate clinical documentation - Self-reported average pain intensity during the last 7 days of = 3 of 10 on the Numeric rating Scale (NRS scale) associated with the primary indication - Fluent in written and spoken English (confirmed by ability to read and comprehend the informed consent form.) - Willing and able to comply with study protocol and assessments, evidenced by completion of the Screening Survey. - Lives in the United States. - Has an active email address and is willing and able to receive email messages. - Is the sole user of an iPhone with iPhone operating systems (iOS) 14 or later capabilities or a smartphone with an Android operating system (OS) 10 or later capabilities with cellular and/or internet access for the duration of the study period. Exclusion Criteria: - Has a comorbid acute pain condition, such as from current injuries - Participation in a clinical trial (including psychotherapy, mindfulness, cognitive training, or drug treatment) within the last 2 months - Initiation or change in primary disease-specific medication for 30 days prior to entering the study - Self-reported substance use disorder within the past 1 year - Daily use of opioids of 30 MME (Morphine Milligram Equivalents) or more - Substance use disorder within the past 1 year. - Initiation or change in central nervous system-active medication (e.g., antidepressants) during the last 2 months. - Participation in a clinical trial within the last 2 months. - Planning to introduce new therapies or change therapies during the study duration - Visual, dexterity or cognitive deficit so severe that precludes the use of an app per investigator judgment. - Severe psychiatric disorder involving a history of psychosis - Other significant medical condition that may confound the interpretation of findings

Study Design


Intervention

Device:
DiNaMo Study App
Study App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy
Placebo App
Placebo App to be used in patients with 1 of the 4 indications of rheumatoid arthritis, fibromyalgia Irritable Bowel Syndrome, Diabetic Neuropathy

Locations

Country Name City State
United States Click Therapeutics New York New York

Sponsors (1)

Lead Sponsor Collaborator
Click Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary To estimate the effect size for changes in pain experience (interference) in the Treatment App group compared to the Digital Control App group Effect size change as measured by the Numerical Rating Scale (NRS) questionnaire, from the lowest (0) to the highest (10) Change from Baseline to Week 4
Secondary To explore the feasibility of remote digital DiNaMo training Study App in participants with chronic pain Feasibility is measured by using User Experience Questionnaire including engagement and experience with the Study App in participants with chronic pain as measured by metrics such as daily app usage and daily time in the app. The questionnaire will ask questions related to the perceived enjoyment, challenges, and related user experience. User experience questionnaire of feasibility recorded on baseline and Week 4
Secondary To estimate the effect size for changes in attention to pain in the Treatment App group compared to the Digital Control App group Change is measured by the Pain Vigilance and Awareness Questionnaire (PVAQ), from the lowest (0) to the highest (5). Change from baseline to Week 4
Secondary To estimate the effect size for changes in pain catastrophizing in the Treatment App group compared to the Digital Control App group Change is measured by the Pain Catastrophizing Scale (PCS) from the lowest (0) to the highest (4). Change from baseline to Week 4
Secondary To estimate the effect size for changes in confidence in dealing with chronic pain in the Treatment App group compared to the Digital Control App group Change is measured by the Pain Self-efficacy Questionnaire (PSEQ) from the lowest (0) to the highest (6). Change from baseline to Week 4
See also
  Status Clinical Trial Phase
Completed NCT04226131 - MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics N/A
Completed NCT04171414 - A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis Phase 3
Completed NCT02833350 - Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA) Phase 2
Completed NCT04255134 - Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN) Phase 4
Recruiting NCT05615246 - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Completed NCT03248518 - Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases N/A
Completed NCT03514355 - MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms N/A
Recruiting NCT06005220 - SBD121, a Synbiotic Medical Food for RA Management N/A
Recruiting NCT05451615 - Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis Phase 3
Completed NCT05054920 - Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis N/A
Completed NCT02037737 - Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting N/A
Recruiting NCT04079374 - Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel Phase 3
Completed NCT02504268 - Effects of Abatacept in Patients With Early Rheumatoid Arthritis Phase 3
Recruiting NCT05496855 - Remote Care in People With Rheumatoid Arthritis N/A
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06103773 - A Study of Single and Multiple Oral Doses of TollB-001 Phase 1
Recruiting NCT06031415 - Study of GS-0272 in Participants With Rheumatoid Arthritis Phase 1
Completed NCT05999266 - The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
Recruiting NCT05302934 - Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
Recruiting NCT04169100 - Novel Form of Acquired Long QT Syndrome Phase 4